PRO-AZITHROMYCINE TABLET
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
28-05-2019
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE)
Fáanlegur frá:
PRO DOC LIMITEE
ATC númer:
J01FA10
INN (Alþjóðlegt nafn):
AZITHROMYCIN
Skammtar:
250MG
Lyfjaform:
TABLET
Samsetning:
AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 250MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
30/100
Gerð lyfseðils:
Prescription
Lækningarsvæði:
OTHER MACROLIDES
Vörulýsing:
Active ingredient group (AIG) number: 0126072001; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2008-09-25
Vara einkenni
PRODUCT MONOGRAPH
PR
PRO-AZITHROMYCINE
Azithromycin Tablets
250 mg
USP
ANTIBACTERIAL AGENT
PRO DOC LTÉE
2925, boul. Industriel
Laval, Québec
H7L 3W9 DATE OF REVISION:
May 28, 2019
Control number: 227600
_PRO-AZITHROMYCINE Product Monograph _
_Page 2 of 71_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
...........................................................................3
INDICATIONS AND CLINICAL USE
................................................................................3
CONTRAINDICATIONS
......................................................................................................6
WARNINGS AND PRECAUTIONS
....................................................................................6
ADVERSE REACTIONS
....................................................................................................11
DRUG INTERACTIONS
.....................................................................................................18
DOSAGE AND
ADMINISTRATION.................................................................................23
OVERDOSAGE
...................................................................................................................24
ACTION AND CLINICAL PHARMACOLOGY
...............................................................25
STORAGE AND STABILITY
............................................................................................28
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................29
PART II: SCIENTIFIC INFORMATION
................................................................................30
PHARMACEUTICAL INFORMATION
............................................................................30
CLINICAL TRIALS
............................................................................................................31
DETAILED
PHARMACOLOGY.................................................................
Lestu allt skjalið
